Detalhe da pesquisa
1.
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
Pharmacogenomics J
; 19(5): 473-479, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30713339
2.
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
Pharmacogenet Genomics
; 27(6): 223-226, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28383355
3.
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients.
Sarcoma
; 2019: 3234205, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31281207
4.
Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.
Clin Sarcoma Res
; 7: 2, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28163887
5.
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Eur J Cancer
; 86: 226-232, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29054076
6.
Tissue factor associates with survival and regulates tumour progression in osteosarcoma.
Thromb Haemost
; 115(5): 1025-33, 2016 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26763081